Table 1.
Emerging cardiovascular risk factors and new preventive strategies
Emerging cardiovascular risk factors | New preventive strategies |
---|---|
“Normal” cholesterol, blood pressure, and blood glucose | Lower thresholds of treatment in high risk individuals |
Oxidation of low density lipoprotein cholesterol | Antioxidants (such as vitamin E) |
Activation of the renin-angiotensin-aldosterone system | Angiotensin converting enzyme inhibitors |
Hyperhomocysteinaemia | Folic acid, vitamin B-6, vitamin B-12 |
Abnormalities of coagulation: | |
Fibrinogen | New antithrombotic approaches (such as preventive use of warfarin, new antiplatelet drugs) |
Factor VII | |
Von Willebrand factor | |
Plasminogen activator inhibitor-1 | |
Lipoprotein Lp(a) | Niacin, oestrogens |
Postmenopausal state | Oestrogens, selective oestrogen receptor modulators |
Chronic infection and inflammation | Antibiotics, anti-inflammatory agents |
Genetic abnormalities | “Targeted” treatment aimed at specific genes or their phenotypic expression |
Nutritional factors | |
Psychological factors | |
Environmental factors | |
Socioeconomic factors |